Canberra, Australia, 27 December 2021 — Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) recently received registration approval from the Australian Therapeutic Goods Administration (TGA) for its Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®).
Firehawk® is a drug-eluting stent (DES), featuring strut in-groove coating and precision target drug-releasing patent technology. It combines the advantages of the bare metal stent and drug-eluting stent, with nearly 600 grooves evenly cut in the hair-thin but extremely hard CoCr alloy. It allows for the precise injection of drugs into the micro-grooves by means of a fully automatic 3D-printed, micro-groove filling, which contributes to the effectiveness of the drug whilst significantly reducing the drug loading.
The approval of the Firehawk® in Australia, following the launch of the Firefighter® and Firefighter® NC balloon catheters not only demonstrates MicroPort®’s outstanding product portfolio in the field of interventional cardiology, but also further expands the company’s global presence. MicroPort® continues to adhere to its brand philosophy of ‘The Patient Always Comes First’ and strives to provide premium total medical solutions for patients and doctors around the world.
About Shanghai Microport Medical (Group) Co., Ltd.
Shanghai MicroPort Medical (Group) Co., Ltd. is a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK). As a leader in high-end innovative medical solutions, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA. In the future, MicroPort® will continue to pursue an innovative, people-centered culture to provide patients and physicians with higher-quality, innovative high-end medical devices and integrated solutions.